newsfilter
← Latest News
Earnings Call Transcripts·

Alkermes plc - AVADEL PHARMACEUTICALS PLC

Okay, cool. Good afternoon, everyone. Day three of our Jeffries London Healthcare Conference. Tail end of the day. We're going to make it through. My name is Akash Chowari. I am a pharma and biotech analyst here at Jeffries, and I have the pleasure of hosting the Alchemies management team and Blair. Alchemys is one of our top picks in SmithCat Biotech, largely based on kind of our growing confidence that orexin agonists are going to be backbone treatments for different types of hyposomal syndications and potentially even more, and I'm sure we're going to talk about that today. Blair, why don't I hand it off to you for some intro questions, and we'll go. Great. Well, thanks for having me here. It's great to see you again. You know, we're coming off a pretty transformational time for the company. This last year, we had a number of data readouts that have kind of moved us into the new space. We had the NT2 data with our Elixir Rexton program, very positive, moving us into phase three. We had positive results on Lumerize for idiopathic hypersomnia, which is moving us forward on registration. And then just a few weeks ago, we announced some positive ADHD data on our ALK7290 program, another orexin agonist that we've entered into the clinic. And so there's a lot been happening with the company. And as we move over into the next 12 months, from now until the end of next year, we probably have about six trials or so reading out over the course of that time. We have our idiopathic hypersomnia study at the end of the year, three phase three programs, NT1, NT2, reading out in the middle of the summer. That's followed by our ADHD phase two dose ranging study in the early fall, and then fatigue in ELKS 4510 right after that. So a lot of catalysts for the company, a lot growth. We're pretty excited to how this portfolio is starting to shape up. Understood. Now, you know, it's interesting. I feel like you guys try to you i remember talking to you and richard kind of in the summer and even going before you try to be humble in terms of where you think erections are going like look if lily wants to go into this area that interesting but we're really focused on this but the range of things that your team is looking at for erections and where you feel like there's a good capital return has really widened beyond just NT1, NT2, and IH to now MDD and ADHD, right? But I know, Blair, you're very, very focused on making sure these are prudent investments and you're really thinking about return on capital. How does ADHD and MDD, what have we seen maybe from the orexin class in NT1 and NT2 IH helped you feel more comfortable that going into these other indications makes sense? Yeah, it's really interesting. I think as you look at moving outside diseases of hypersomnolence, there's a lot of interesting places that you can take these molecules. And we really view this from a first principles perspective. We did a lot work on neurotransmitter release. We did a work on basic pharmacology to really understand how can you take these into new areas, where are you going to have the most tangential outcome? What's similar to wakefulness that you could apply in a broader neuroscience indication? And things like ADHD and MDD fall right in that category. So, for example, we see in MDD, for ejemplo, that we can get a really strong synergistic effect in serotonin release in the prefrontal cortex and other areas of the brain synergistically when you give SSRIs and SNRIs. That's a really interesting finding, which means we're actually going after the root cause of depression, not trying to treat sleep to get at depression, if you know what I mean. So I think the same is true for ADHD. We were looking very carefully at acetylcholine release. We're looking at a lot of behavioral models in animals. And so these things make a lot sense as you look at applying this methodology into other areas of neuroscience. And that's kind of our philosophy of what's going to give us the best return, but also has a very strong probability of success. Understood. Now, it's interesting. If you look at some of the FDA review documents, the Japanese review documents Takeda actually was in pretty in-depth discussions with the agencies about getting a cognition benefit for the orexin in type 1. And it goes directly to your point where I think people think, all right, well, this is going to make you feel more awake. that's why, you know, you're going to have a benefit in certain subscales. But it does seem like there is a element of cognition improvement that's distinct from simply weightfulness improvement. I know your team has a view on this as well. What have you learned looking at some of the FDA's interactions with Takeda, but then also some of the data you have in-house? Well, I think we've seen across our programs that these mechanisms have cognitive benefit. And in fact, when we look at our existing programs, our narcolepsy type 1 study, our narcolepsie type 2 study, we included direct cognition measurements as part of those studies. We were able to show very clearly that you could take patients from moderate and severe levels of cognitive deficit to normal. And we see it consistently across the programs and in a dose-responsive way. So both us as well as Takeda have recognized this in our programs. And both of us have had interactions with the FDA about what how do you approach this do you do you apply this does it show up in your clinical table do you actually get a separate claim for that I think more clinical work would be needed there to to demonstrate that but we definitely feel that it's it's this is not being pseudo-specific that in fact you are getting a separate cognitive benefit outside of just sleep and that also applies to fatigue as well we did exactly the same thing with fatigue in our NT1 and NT2 studies, we put the PROMIS fatigue scale in each of those studies and saw similar outcomes to what we saw with cognition. Understood. Now, I think one of the more under-discussed data sets, but probably quite important in this space, was the maintenance data that your team showed earlier this year in type 1, but also type 2 narcolepsy. And what kind of really stood out to me was, A, that patients chose to get on higher doses because they felt increasingly probably comfortable with the safety profile. But then, B, there was actually a deepening of response, not just on MWT, where I think there's been a lot of focus on, but on multiple different assessments. What did you learn from that maintenance data that you can apply to your development program outside of hypersomnolence indications? Well, I think your point is really well taken that as you look at some of these new mechanisms, understanding the depth and duration of effect is really interesting. And, you know, you have to pick an arbitrarily end point when you run these studies. It could be four weeks, six weeks, eight weeks, whatever. But what we see is that with prolonged use, you're getting continued improvement. We also find, and you saw this in our NT2 study, that patients may have a preferred dosing lane. It may be you're randomized in the randomized trial to a dose that's not optimal for you, but when you optimize that dose for a patient, they get a continued benefit moving forward. So we see that in some of our programs as we think of ADHD, as we Think of MDD, trying to understand how the effect size evolves over time is actually going to be an important element of our studies. Understood. Now, you know, you have idiopathic hypersomnia study um reading out either end of year or next year sandy's looking at me making it right um but it's interesting i talked a lot of masters are like oh i love the 2020 setup 2027 setup for alchemies i'm just nervous into this ih data and i don't sense the same let's say nervousness from your team or that binary nature? And why is that the case, right? Like, why does your team, because I feel like your team's getting increasingly confident. We are going to be moving forward in IH. We just don't know exactly what that format's going to be. Yeah, I mean, it's an interesting question. I think people, as you think about these indications, it is natural for people to want to segregate. Say you have an NT2 patient, an NT1 patient or an IH patient, what I think a lot of folks aren't realizing is that there's a lot flow between these patient populations. The diagnosis between NT1 and NT2 is a little vague sometimes. Sometimes patients have cataplexy that's not recognized, but they're classified as an MT2, for example. On the other end, we see a lot movement of patients between an IEH diagnosis and an NT2 diagnosis. As we think of the patient population that we're studying, we see it as being very similar to an NT2 population in the heterogeneity and how they respond to drug. They both have intact orexin tone, and so we would expect to see a similar effect size. We're using the same dosing, once daily dosing. We're the same doses. I think the main difference between the NT2 and the IH population is you do have a subgroup. You have a group of long sleepers who are a little different phenotypically, but those Those long sleepers still experience excessive daytime sleepiness. That's still at rates similar to the NT2 group. And what we've seen with orexin agonism is that as you give super therapeutic levels of orexins, that you can drive wakefulness. You can drive them in normals. You can Drive them in NT2 population. So we would expect to see the long sleeper's perform well as well. I think where people see the risk, I guess, is that we're kind of pushing new boundaries here. This is the first time that anorexin agonist has been used in a broad IH population. And what we can't do right now is just quantify that effect size. That's the purpose of this study. How do you design your phase three to have a statistical outcome that gets you a clinically meaningful outcome for patients? Understood. But I will say, you guys have still said, look, when we think about the type of signal we're looking at, two to three points explicitly adjusted on ESS seems like a reasonable bar. Does that still hold true? Yeah, I mean, that's a clinically meaningful movement on the scale. The unmet need in IH is tremendous. There's really one branded drug there, which is Zywave right now. And oxybetes are great drugs, but they're not for everybody. And I think an orexin agonist in the IH space is heavily needed. And remember, when we started our program, we started working in narcolepsy type 1, narcolepty type 2. We had some hesitation about IH because of IRA concerns and other things. the patient community came to us. They were very clear. They're looking for medicines here. And so if you can show a clinically meaningful benefit in any way, they're more than happy to utilize your drug or to consider using your drug. Understood. Now, I remember when the NT2 data came out and your team was having discussions, you talked about, you know, we're going to look at a BID formulation and maybe that we get a little better target coverage kind of in those last reads i want you to kind of update but one of the interesting things that i remember you know you and richard were mentioning is you know we're seeing kind of two phenotypes you know one group that would benefit from maybe bid dosing because we're seeing it in the curves and then it drops off and then maybe another you know group where even if we dose more we wouldn't necessarily have a benefit do you still have that view that there's like maybe two distinct phenotypes now that you actually have maintenance data, right? And that's really where it gets interesting, and can you talk a bit about that? Are there two different phenotypes in MWT, and then are there two different phenotypes in ESS? Do you still think that's the case here? Well, yeah, I think as you look at the patient population here, within NT2, their sensitivity to orexin agonism can vary, and I don't know whether it's two distinct populations or it's a spectrum of response. And so when you look at our OLE data, for example, you see more of a spectrum of response. You see a group of patients at different dose levels who perform differently and then in time all normalize, which is great. I think the one thing, though, that we saw with the MWT test in our NT2 study is that that's a very sensitive test to specific time points in the course of a day. In a subset of patients, we saw that they were less responsive in the afternoon. We didn't see that in the total population. So that group would benefit best from a split dose. And it was actually the impetus of us putting split dosing across our programs. Have you looked at split dosING in a maintenance setting yet? This will be the first result that we'll see with split dose performance in a clinical study. And I think that's part of why people are very interested in this data set. Understood. Now, I guess maybe going into phase three. One of the things that your team's hinted at is, look, the dose range we explored here may not be actually the doses we take into phase three, and we feel increasingly comfortable about the safety profile of these erections. So can you talk about, especially in your maintenance studies, what you're seeing in terms of AEs that are actually longer lasting versus those that are really just acute ones that you get as your body's tolerating the drugs, but then they wane away over time? Yeah, it's a good question. I think what we've seen across our programs and other programs that other companies have run is there is an adaptation that happens as a patient goes under the drug first time. And you do get some things like insomnia, for example, as a patient adapts to the new drug. That's sort of your circadian rhythm adjusting to a new event. Sometimes you'll see that with headache. We saw in our NT1 trial some visual disturbances that were associated with that early onset piece. Really, the only long-term type AEs that you typically see, it's really polychorea, which is a frequency of urination. And we tend to see it's mainly mild to moderate. It tends to be persistent in those patients who have it, but it doesn't tend to bother them. It doesn't lead to discontinuations. And we also see that in response forms on global impression and things like that from patients in studies. They love being on the therapy still. They like the benefits it's giving. It's not disruptive to their treatment. Understood. And then maybe thinking about face reason tweaks you can make in learnings you had. you mentioned, you know, maybe there's a titration scheme. How does titration, let's say, implemented within a phase three help deal with the rate of overall AEs? And how fast would that titration actually be for some of your trials? Yeah, so the only area where we think a tituration like that could help is in your NT1 population. What we saw in particular in our NT1 trials is that if you took a patient, they all have zero orexantone, and if you were to take them and put them on the highest dose right away, you would tend to see more of those early tolerance issues, and so what we've done for our phase three, actually, is we step them first through an active dose for a couple weeks, and once they've been on the active dose for several weeks, if they've randomized to the high, then they'll move to the high dose, and what that does is give them a little bit of a ramp so they can acclimatize to the new drug we were just moving them and pushing them too fast understood and do you feel like that might actually lead to you know differ differentiated safety relative to some of the decayed assets that we've seen in in NT1 it it may it's really hard to compare the different drugs where we are in the dose curve and and and how we're dosing once daily versus their split dose etc so I think you know our goal in this trial was to was to maximize efficacy and try to minimize our AE profiles as much as possible. Too soon to say whether it'll differentiate on that end. Understood. Now on ADHD, and it's interesting, again, there's like investor perception, and then you talk to strategics as well. And then we talked to you. You're not, you know, it wasn't placebo. It doesn't sound like there was a placebo separation. You seem to be relatively unbothered with that. And I think the biggest tell is that when we look at your phase two study. You had every potential, enrich patients with baseline sleepiness, you know, enhance the trial powering. Your stat design, you've talked about, you know efficacy in line with certain stimulants. You're powered really to deliver that in phase two. That's a very big, you know internal versus external kind of contrast right now and I'm sure you felt that too and with you know, talking to people. What do you see when you have the data in-house that maybe we're missing externally right now? Well, I think when people are looking at the data set in the phase 1b and they start talking about placebo comparison, they're trying to make a trial, hit a trial that it wasn't. It never was. This was a safety trial where we're trying to look at patients within an inpatient setting over two weeks. So by the end of the trial, we actually only had eight placebo patients on the on the study what we've seen and makes us confident in in in the mechanism is in that 1b study we had a number of different things that we put in there a number different patient reported outcomes physician reported outcomes we put objective measures in and what we saw across those is we saw consistent response we saw robust responses it was consistent regardless of how it was measured we saw at our high dose we We saw a CGIS change of two in a two-week period of time. That's a pretty profound change, regardless of how you look at that. So for setting the size, though, to look at are you Vyvanse-level efficacy, you need that big Phase II study. It has to be powered correctly. We have the dose ranging so that we can look at dose response. The purpose of the two studies is very different. And in order to do the bigger study, you're literally looking at more of an outpatient setting. It's a four-week outpatient versus R1B, which is a two-week inpatient. Two very, very different characteristics. Understood. Another trial you have coming up next year, I would argue probably flying under the radar, is your fatigue study, right? So an MS and Parkinson's study. Fatigue. And, you know, you guys have an underlying biological hypothesis, and then you're really curious what plays out in the clinic. So help us understand, why choose MS and Parkinson's as kind of your two initial fatigue indications? And what are kind of two different clinical development pathways that branch out of that result? Well, I'll start with the last question first, because when we looked at fatigue, fatigue is one of those areas that when you look at a lot of neuroscience as a whole and a lot of neurogenic disease, you see fatigue really plaguing a lotof these patients. And we were hearing clearly in some of these programs how disruptive it is to patients' lives. And so you can think of big indications, things like chronic fatigue and things like that. You can think of cancer treatment fatigue. We picked Parkinson's disease fatigue and MS fatigue to start because what we want to try to do is characterize this disease a little more thoroughly. And one of the things you tend to hear when people talk about fatigue, because they don't know what the ideology is. They tend to talk about central fatigue and peripheral fatigue. So central fatigue being this exhaustion that you feel mentally. MS patients tend to describe that as their primary fatigue. When you talk to Parkinson's patients, they tend to subscribe more of a peripheral fatigue, a muscular fatigue, this bone tired muscles. And you almost could expect that if you think of the diseases, it's what they're experiencing that's different. So they could be just describing the same disease in a different way we want to know how um orexin agonism works in these two different types and then we also want to test their individual scales so the promise fatigue scale the ms fatigue scale to pd fatigue scales to sort of see which is the most sensitive and and accurate to to assess these and thenwe can meet with the fda to talk about what's our path forward to develop these andthen to go into broader markets thereafter so it's it's actually A data-rich study is going to tell us a lot, and it will really point to what it's going to take to take it not only in these indications, which are large, but into the bigger indications that are more broad. Now, I can tell you it did not surprise me to see a company like Lilly that has a vested interest in Alzheimer's look at an orexin agonist as maybe an asset they wanted in their pipeline. You guys have alluded to this, but I'd love to get your take as well. Because I think there's a provocative argument that this could be an Aricept, right? It's something that actually, it's a cognitive enhancer. It's relatively tolerable. It could be used as an adjunct therapy. So, you know, companies that are trying to commercialize Alzheimer's. Do you see validity in that way of, you don't necessarily have trials there right now. But what would be the use of an orexin in an adjunct Alzheimer's setting? No, it's a great question. I think if you look at a lot of the therapies for Alzheimer's right now, they're taking a very different approach to treatment. And I think when you take something like a memantine that's had a lot of benefit in use, but you could really improve on that with something that is driving a central mechanism. So adjunctive therapy in Alzheimer's is definitely an interesting area, And we've identified a number of areas in neuroscience where you could use this. It comes with complications, as you can imagine, elderly population. There's things going on with the brain and the ability to do that. So, you know, when we talk about probabilities of success and investment, some of the ones we've picked now are a little more proximal. But that's definitely somewhere you could take orexin agonism. Understood. Now, I think there's been – it's funny. I've never seen more people bring just a calculator. They're like, here's the prevalence, here is a number, and then here is your peak sales. You'll see that sometimes when we talk about pancreatic cancer. But I'm sure you've heard a similar kind of way of thinking when you think about narcolepsy and pricing expectations. You know, Takeda came out, and they came at a premium to sodium oxibate. And every investor is like, well, TAKEDA, why did you do this? You could have priced more. Why do you think Takeda did choose to price their drug where they did? How does that allow them to actually get rapid access out of the gate? And then how does that change your pricing decisions when your drug gets into the market? Well, look, I think as Takedas coming out with their drug, they're building a new market, a whole new mechanism that they're going to have to educate patients on, educate physicians on. They're working with the payers to work through that system. They also have a global business that they are putting in place, and they have a lot of considerations that they're looking at. And by any measure, that's a high-priced medication. And I think if you look at diseases of hypersomnolence and just kind of the treated populations, you're in the $25-ish billion range for an addressable market. So these are big markets. I think Takeda is balancing the best it can do with the business and how it wants to do and how its assessed access. And we'll be watching carefully to see how that performs. Obviously, we have a lot of flexibility with our program, three different indications, multiple doses, single dose, split dose. So there's a lot flexibility in how we approach that in the future, and we'll see how things progress and go from there. Understood. Last question before we let you go. So I was surprised, and actually our team went to Asia and spoke with Decadia, and I think they also were surprised to see an LDL increase with TAC861. And it showed up, I don't think they had published on that previously. Have you looked at impact of orexin? Do you think that's maybe a non-target effect or maybe something related to an individual scaffold? I mean, I think it's something we haven't seen in our program, so I'm not sure it's necessarily an on-target effect. We do know, for example, that there's an interplay between weight and lipids as patients go through their disease state. So when we wash people out of their existing drugs, for ejemplo, they'll eat excessively to stay awake. And so you'll see challenges there. So I don't know whether it's a function of disease shining through or whether it is something different, but again, not something we've seen in our program to date. But we'll look for it in our pastries. Understood. Wonderful conversation. I really did enjoy it. Thanks so much. Thanks, Scott.

Company
AVADEL PHARMACEUTICALS PLC
Keywords
AVADEL PHARMACEUTICALS PLC